These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6338971)

  • 41. Sickle cell anemia. Pathophysiology and treatment.
    Alavi JB
    Med Clin North Am; 1984 May; 68(3):545-56. PubMed ID: 6205230
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Viscosity and filtrability measurements of sickle-cell suspensions in the development of anti-sickling drugs.
    Ohnishi ST
    Blood Cells; 1982; 8(1):79-87. PubMed ID: 7115980
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The treatment of sickle cell disease. A historical and chronological literature review of the therapies applied since 1910.
    Aluoch JR
    Trop Geogr Med; 1984 Dec; 36(4):S1-26. PubMed ID: 6396910
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alternative aspirins as antisickling agents: acetyl-3,5-dibromosalicylic acid.
    Walder JA; Zaugg RH; Iwaoka RS; Watkin WG; Klotz IM
    Proc Natl Acad Sci U S A; 1977 Dec; 74(12):5499-503. PubMed ID: 271972
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.
    Zahr RS; Hankins JS; Kang G; Li C; Wang WC; Lebensburger J; Estepp JH
    Am J Hematol; 2019 Jan; 94(1):E27-E29. PubMed ID: 30359463
    [No Abstract]   [Full Text] [Related]  

  • 46. Effects of carbon dioxide and pH variations in vitro on blood respiratory functions, red blood cell volume, transmembrane pH gradients, and sickling in sickle cell anemia.
    Ueda Y; Bookchin RM
    J Lab Clin Med; 1984 Aug; 104(2):146-59. PubMed ID: 6431043
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Urea, urease, cyanate, and the sickling of hemoglobin S.
    Nalbandian RM; Nichols BM; Stehouwer EJ; Camp FR
    Clin Chem; 1972 Sep; 18(9):961-4. PubMed ID: 5052097
    [No Abstract]   [Full Text] [Related]  

  • 48. Measurement of red cell sickling: a method for studying the efficacy of antisickling drugs under physiological conditions.
    Ohnishi ST; Hashimoto K; Sato T
    Can J Physiol Pharmacol; 1983 Aug; 61(8):941-5. PubMed ID: 6627133
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of in vitro sickling by liposome-mediated transport of amino acids into intact human red blood cells.
    Kumpati J
    Biochem Biophys Res Commun; 1982 Mar; 105(2):482-7. PubMed ID: 7092867
    [No Abstract]   [Full Text] [Related]  

  • 50. Increasing haemoglobin oxygen affinity to prevent sickling: abnormal haemoglobin variants as models.
    Franklin IM; Huehns ER; Rosemeyer MA
    Br J Haematol; 1986 Oct; 64(2):319-29. PubMed ID: 3778826
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro inhibition of the rate of erythrocyte sickling by RMI 11,071A and its possible mechanism.
    MacKenzie RD; Gleason EM; Schatzman GL; Cawein MJ
    Proc Soc Exp Biol Med; 1979 Oct; 162(1):224-6. PubMed ID: 504233
    [No Abstract]   [Full Text] [Related]  

  • 52. Increased survival of sickle-cell erythrocytes after treatment in vitro with sodium cyanate.
    Gillette PN; Manning JM; Cerami A
    Proc Natl Acad Sci U S A; 1971 Nov; 68(11):2791-3. PubMed ID: 5288258
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of carbamylation of Hb-S on the sickling process.
    May A; Huehns ER; Beaven GH
    Clin Sci; 1972 Apr; 42(4):20P-21P. PubMed ID: 5020278
    [No Abstract]   [Full Text] [Related]  

  • 54. Do amino acids reverse the sickling of erythrocytes containing hemoglobin S?
    Shirahama K; Kubota S; Yang JT
    Hemoglobin; 1980; 4(2):149-55. PubMed ID: 7390860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
    Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
    Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mode of transport and possible mechanism of action of L-phenylalanine benzyl ester as an anti-sickling agent.
    Acquaye CT; Young JD; Ellory JC; Gorecki M; Wilchek M
    Biochim Biophys Acta; 1982 Dec; 693(2):407-16. PubMed ID: 7159585
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modification of sickle hemoglobin by acetaldehyde and its effect on oxygenation, gelation and sickling.
    Abraham EC; Stallings M; Abraham A; Garbutt GJ
    Biochim Biophys Acta; 1982 Jul; 705(1):76-81. PubMed ID: 7115734
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes.
    Beddell CR; Goodford PJ; Kneen G; White RD; Wilkinson S; Wootton R
    Br J Pharmacol; 1984 Jun; 82(2):397-407. PubMed ID: 6733364
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Pharmacology for Pediatricians. II. Antisickling agents, with special reference to new vasoerythroactive drugs.
    Cho YW; Aviado DM
    J Clin Pharmacol; 1982 Jan; 22(1):1-13. PubMed ID: 7037870
    [No Abstract]   [Full Text] [Related]  

  • 60. Deoxyhemoglobin S: solubility vs. erythrocyte sickling.
    Vedvick TS; Koenig HM; Itano HA
    Clin Biochem; 1975 Aug; 8(4):288-90. PubMed ID: 1157297
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.